A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan

Isao Kawaguchi,Kazuaki Chayama,Yuri Sanchez Gonzalez,Suchin Virabhak,Dominic Mitchell,Cammy Yuen,Hiromitsu Kumada

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan

2019

Isao Kawaguchi
Kazuaki Chayama
Yuri Sanchez Gonzalez
Suchin Virabhak
Dominic Mitchell
Cammy Yuen
Hiromitsu Kumada

Introduction The objective of the study was to evaluate the cost-effectiveness of glecaprevir/pibrentasvir versus other direct-acting antivirals (DAAs) for treating chronic hepatitis C virus (HCV) infections in Japan.

Keywords:

Cost-effectiveness analysis
Pibrentasvir
Medicine
Diabetes mellitus
Anesthesia
Glecaprevir
Hepatitis C virus
Hepatitis C
Internal medicine
Infectious disease (medical specialty)
Glecaprevir / pibrentasvir
Grazoprevir
Sofosbuvir
Ledipasvir
Demography
Elbasvir
cost effectiveness
Daclatasvir

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations